SF

Morgan Stanley reported Q3 2026 earnings of $3.03 per share, beating consensus estimates of $2.83 and revenues of $20.34 billion, surpassing expectations by 3.04%. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends, suggesting near-term underperformance despite strong quarterly results. The stock has gained 5.1% year-to-date, underperforming the S&P 500's 14% gain.

Staar Surgical stock surged nearly 8% after Stifel analyst Thomas Stephan upgraded the company to 'buy' from 'hold' and raised the price target to $31 from $28. The upgrade was driven by expectations of higher sales in the second half of 2026, particularly for the company's surgically implanted lenses in China, and recognition of Staar's potential as an acquisition target and product developer.